Business Context and Reporting Period
This Form 8-K was filed by Inmune Bio, Inc. (INMB) on March 23, 2021, reporting an event that occurred on March 21, 2021. The company is a Nevada corporation with principal executive offices in La Jolla, California, and its common stock trades on The NASDAQ Stock Market LLC.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding a specific corporate event rather than a periodic financial report.
Material Changes
The material event reported is the adoption of a Rule 10b5-1 trading plan by CTI Holdings, Inc. ("CTI"). Key details include:
- Shares Involved: 70,000 shares of Inmune Bio common stock.
- Ownership Percentage: Approximately 42% of the shares owned by CTI.
- Plan Duration: Commences March 22, 2021, and terminates March 22, 2023.
- Related Party: Tim Schroeder is the majority shareholder of CTI and a member of Inmune Bio's board of directors.
Guidance, Outlook, and Risks
The filing provides no guidance, outlook, or management commentary regarding the company's business operations or financial future. The primary purpose of the Rule 10b5-1 plan is to allow insiders to trade shares for personal asset diversification and tax planning strategies without possessing material non-public information. The company states it has no obligation to report modifications or terminations of the plan except as required by securities laws.
Investor Verification Checklist
- Verify the total number of shares owned by CTI Holdings, Inc. to confirm the 42% calculation.
- Monitor future Form 4 filings to track actual transactions executed under this trading plan.
- Review the company's periodic reports (10-K/10-Q) for financial performance data not included in this 8-K.